Patents by Inventor Jichen Zhao

Jichen Zhao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FUSED RING-SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20250084078
    Abstract: Disclosed in the present invention is a compound as represented by formula (IA) or formula (IC) or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof. The definition of each group in the formula is shown in the description for details. Further disclosed are a pharmaceutical composition containing the compound and the use thereof in the preparation of a drug for preventing and/or treating diseases or conditions related to HPK1 activity.
    Type: Application
    Filed: January 3, 2023
    Publication date: March 13, 2025
    Applicants: GENFLEFT THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEFT THERAPEUTICS CO., LTD.
    Inventors: Jichen ZHAO, Fusheng Zhou, Chonglan LIN, Ling PENG, Wan HE, Huabin YANG, Zhen LI, Tao ZHANG, Kai MA, Jiong LAN, Qiang LU
  • FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20240182465
    Abstract: A compound having HPK1 inhibitory activity as shown in formula (IA) or (IC), and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, and a pharmaceutical composition containing the compound, and use of same in preparation of a drug for preventing and/or treating diseases or conditions associated with HPK1 activity.
    Type: Application
    Filed: March 3, 2022
    Publication date: June 6, 2024
    Applicants: GENFLEET THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.
    Inventors: Fusheng ZHOU, Jichen ZHAO, Wan HE, Chonglan LIN, Ling PENG, Huabin YANG, Zhen LI, Xiaoling LAN, Mei GE, Qian DING, Xiang YU, Jiong LAN, Qiang LU
  • PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20240174691
    Abstract: Disclosed are a pyrimidine-fused cyclic compound having an inhibitory effect on KRAS gene mutation, or a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, and a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating cancer.
    Type: Application
    Filed: March 17, 2022
    Publication date: May 30, 2024
    Applicants: GENFLEET THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.
    Inventors: Tao JIANG, Fusheng ZHOU, Leitao ZHANG, Lijian CAI, Feng YAN, Jichen ZHAO, Jiong LAN, Qiang LU
  • FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF
    Publication number: 20230203060
    Abstract: Provided are a fused tricyclic compound having the structure shown in formula (I), a pharmaceutical composition thereof, and a use thereof. The fused tricyclic compound serves as a selective inhibitor of KRAS mutation, and has high activity, good selectivity. and reduced toxic side effects.
    Type: Application
    Filed: May 27, 2021
    Publication date: June 29, 2023
    Inventors: Fusheng ZHOU, Tao JIANG, Yingtao LIU, Jichen ZHAO, Wan HE, Zhubo LIU, Ling PENG, Lijian CAI, Leitao ZHANG, Chonglan LIN, Huabin YANG, Tao ZHANG, Jiong LAN
  • MLL1 INHIBITORS AND ANTI-CANCER AGENTS
    Publication number: 20220380371
    Abstract: The present invention provides a compound of Formula (I): or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating a disease or condition mediated by mixed lineage leukemia 1 (MLL).
    Type: Application
    Filed: September 18, 2020
    Publication date: December 1, 2022
    Inventors: Ming LI, Kevin Kun Chin LIU, Chunliang LU, Zhuming SUN, Jichen ZHAO, Yihui ZHU
  • OXAAZAQUINAZOLINE-7(8H)-KETONE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF
    Publication number: 20220251109
    Abstract: An oxaazaquinazolin-7(8H)-ketone compound with a selective inhibition effect on KRAS gene mutation and pharmaceutically acceptable salts thereof, stereoisomers, solvent compounds or prodrugs (as shown in formula I or formula II, see the details of the definition to each group in the formulas in the specification), as well as the pharmaceutical composition containing the compound, and the application thereof in preparation of cancer medicine.
    Type: Application
    Filed: April 28, 2020
    Publication date: August 11, 2022
    Applicants: GENFLEET THERAPEUTICS (SHANGHAI) INC., ZHEJIANG GENFLEET THERAPEUTICS CO., LTD.
    Inventors: Fusheng ZHOU, Lijian CAI, Tao JIANG, Jichen ZHAO, Yingtao LIU, Jinzhu ZHAO, Leitao ZHANG, Zhubo LIU, Ling PENG, Wan HE, Huabin YANG, Tao ZHANG, Qian DING, Biao ZHENG, Qiang LV, Jiong LAN
  • Alkyl pyrrolopyrimidine analogs and methods of making and using same
    Patent number: 11001586
    Abstract: The present disclosure is concerned with benzo annulene compounds that are capable of inhibiting a Mer tyrosine kinase and/or a Tyro3 tyrosine kinase and methods of treating a bacterial infection, a viral infection, and/or a disorder of uncontrolled cellular proliferation such as, for example, a cancer, using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: May 11, 2021
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Xiaodong Wang, Hongchao Zheng, Jichen Zhao, Weihe Zhang, Stephen V. Frye
  • ALKYL PYRROLOPYRIMIDINE ANALOGS AND METHODS OF MAKING AND USING SAME
    Publication number: 20200062764
    Abstract: The present disclosure is concerned with benzo annulene compounds that are capable of inhibiting a Mer tyrosine kinase and/or a Tyro3 tyrosine kinase and methods of treating a bacterial infection, a viral infection, and/or a disorder of uncontrolled cellular proliferation such as, for example, a cancer, using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: November 17, 2017
    Publication date: February 27, 2020
    Inventors: Xiaodong Wang, Hongchao Zheng, Jichen Zhao, Weihe Zhang, Stephen V. Frye